Table 1 Interactions between baseline risk, treatment-related harm (Rx-harm) and competing risk (CR) when chemotherapy reduces breast cancer mortality by 15%.
From: Competing risk and heterogeneity of treatment effect in clinical trials
Risk of Breast CA Death | No Rx-harm or CR | Rx-harm (1.5% absolute rate) but no CR | Rx-harm & CR is: | ||
|---|---|---|---|---|---|
Low (10%) | Moderate (25%) | High (50%) | |||
(10-yr CA Mortality) | Absolute Risk Reduction/Number Needed to Treat | ||||
Low (10%) | .015/67 | 0/8 | -.002/-667§ | -.004/-267§ | -.007/-133§ |
Moderate (25%) | .038/27 | .023/44 | .019/53 | .013/76 | .004/267 |
High (50%) | .075/13 | .060/17 | .053/19 | .041/24 | .022/44 |